EUVIMEDEUVIMED entdecken
Crossref

Engineered Probiotic Saccharomyces boulardii Produces Functional Insulin With Long‐Acting Effect in Mice Model

Jefferson J Feng, Di Yu, Lydia Nyasae, Rachel Lee, Fenfen Zhou, Yongrong Zhang, Hua Yu iD

Biotechnology Journal · 2026

DOI: 10.1002/biot.70197 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology Journal, 2026. Verfasst von Jefferson J Feng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Fzata Inc., Halethorpe, Maryland, USA. Hauptthemen laut MEDLINE: Saccharomyces boulardii, Insulin, Probiotics, Diabetes Mellitus, Experimental. Die Arbeit nennt 16 Literaturangaben. Gefördert von: NIH HHS, National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetes mellitus affects over 500 million people globally, with current insulin therapies relying on subcutaneous injections that compromise the liver's natural role in glucose regulation and suffer from poor patient compliance. Oral insulin delivery offers a physiological alternative but faces challenges, including gastrointestinal degradation and poor absorption. Here, we engineered Saccharomyces boulardii , a probiotic yeast with established gastrointestinal survival capabilities, to secrete a long‐acting Insulin‐Fc fusion protein (Ins/Fc). Using strong constitutive promoters (TDH3 and TEF1), we achieved stable expression in lead strains FZ030 and FZ032. The secreted Ins/Fc fusion protein demonstrated functional bioactivity in cultured cells and in diabetic mice. This represents the first successful engineering of S. boulardii to produce a functional insulin and establishes a promising platform for developing oral insulin delivery systems.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Saccharomyces boulardiiInsulinProbioticsDiabetes Mellitus, ExperimentalAnimalsMiceRecombinant Fusion ProteinsHumans

Stichwörter der Autor:innen

Saccharomyces boulardiibioactivitydiabetesinsulinoral deliveryprobiotics

Substanzen

InsulinRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Fzata Inc., Halethorpe, Maryland, USA.
  • Department of Microbial Pathogenesis, University of Maryland, Baltimore, Maryland, USA.

ORCID-Profile: Hua Yu

Förderung

  • NIH HHS
  • National Science Foundation

Zitieren

APA

Feng, J. J., Yu, D., Nyasae, L., Lee, R., Zhou, F., Zhang, Y., & Yu, H. (2026). Engineered Probiotic Saccharomyces boulardii Produces Functional Insulin With Long‐Acting Effect in Mice Model. Biotechnology Journal. https://doi.org/10.1002/biot.70197

Vancouver

Feng JJ, Yu D, Nyasae L, Lee R, Zhou F, Zhang Y, et al. Engineered Probiotic Saccharomyces boulardii Produces Functional Insulin With Long‐Acting Effect in Mice Model. Biotechnology Journal. 2026. doi:10.1002/biot.70197

BibTeX
@article{Feng2026,
  author = {Feng, Jefferson J and Yu, Di and Nyasae, Lydia and Lee, Rachel and Zhou, Fenfen and Zhang, Yongrong and Yu, Hua},
  title = {Engineered Probiotic Saccharomyces boulardii Produces Functional Insulin With Long‐Acting Effect in Mice Model},
  journal = {Biotechnology Journal},
  year = {2026},
  doi = {10.1002/biot.70197}
}
Kostenlos starten →